1. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, Locatelli F, Marchetti M, Morra E, Rebulla P, Visani G, Tura S, Italian Society of Hematology (2002) Evidence- and consensus-based practice guidelines for the therapy for primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 87:1286–1306
2. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC, Damaj G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104:321–327
3. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E (1998) A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 83:910–935
4. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(Suppl 2):13–19
5. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization (WHO) International Working Group (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671–3674